Frequency scanning with intermittently scanned CGMS (is-CGMS) is associated with glycemic indices. No data is available for its correlation with fear of hypoglycemia (FOH) , a well-known factor affecting quality of life and glycemic control in type 1 diabetes (T1DM) . The aim of the study was to analyze the association of scanning frequency with glycemic indices and FOH in T1DM patients using is-CGMS. T1DM patients using is-CGMS were eligible. Clinical data, Ambulatory Glucose Profile (AGP) reports were obtained from medical records. FOH was assessed using Hypoglycemia Fear Survey II (HFS-II) . We included 77 consecutive patients (58 females) , 38 were treated with insulin pump, 39 with multiple daily injections. Their mean age was 34.1+/-10.2 years and T1DM duration 14.7 +/-12.0 years. Mean glycemic indices were as follows: mean glucose - 155.8+/-29.8 mg/dl; GMI - 53.3+/-7.5 mmol/mol; TIR - 66.4+/-17.8%; TB70 - 4.5+/-4.1%; TB54 - 0.6+/-1.2%; TA180 - 29.2 +/-17.9%; TA250 - 9.6+/-10.4%; %CV - 36.7+/-8.3. The average scanning frequency was 13.8+/-7.8 scans/d. Mean HFS II scores were 16.1+/-7.2 and 18.7+/-12.2 in behavior and worry subscale, respectively. Correlation was found between scanning frequency and mean glucose, GMI, TIR, TB70, TA180, TA250, %CV and HFS-B (p<0.for all statistics) .

In summary, for the first time, we report that higher scanning frequency is associated not only with better glycemic indices but also with less FOH in T1DM patients using is-CGMS. This constitutes a new argument for advising T1DM patients frequent scanning when using is-CGMS.

Disclosure

J.Hohendorff: Advisory Panel; Abbott. M.Malecki: Consultant; Abbott Diabetes, Boehringer Ingelheim International GmbH, Lilly Diabetes, Novo Nordisk, Speaker's Bureau; Ascensia Diabetes Care, AstraZeneca, Bayer AG, Merck & Co., Inc., Mundipharma, Servier Laboratories. P.W.Witek: Other Relationship; Abbott, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, Medtronic, Merck & Co., Inc., Novo Nordisk, Roche Diabetes Care, Sanofi-Aventis Deutschland GmbH. M.Kania: None. M.Sudol: None. K.Hajduk: None. A.Stepien: None. K.Cyganek: Speaker's Bureau; Abbott Diabetes, Ascensia Diabetes Care, Bausch Health, Canada, Boehringer Ingelheim International GmbH, Lilly Diabetes, Medtronic, Novo Nordisk, Roche Diabetes Care. B.Kiec-wilk: n/a. T.Klupa: Advisory Panel; Abbott, BIOTON S.A., Sanofi, Research Support; Medtronic, Speaker's Bureau; Ascensia Diabetes Care, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.